Han Kim

Han Kim is a seasoned professional in the biopharmaceutical field, currently serving as Senior Director at Bolt Biotherapeutics, Inc. since June 2021, where leadership of a multifunctional team focuses on the development of Claudin 18.2 ISAC from discovery to IND. Previously, at AbbVie since January 2010, Han Kim progressed from Principal Scientist-Discovery Group Lead to Principal Scientist II-Translational Oncology Research Lead, contributing significantly to translational strategy and leading teams to develop first-in-class cancer therapeutics, resulting in multiple IND filings. Prior roles include Group Leader in Biomarker Discovery at Facet Biotech and Oncology Target Validation at PDL BioPharma, as well as a postdoctoral researcher at Columbia University Vagelos College of Physicians and Surgeons. Han Kim holds a Ph.D. in Microbiology (Immunology) from Columbia University and a BA in Biochemistry from the University of Pennsylvania.